These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23958808)

  • 1. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.
    Snape MD; Philip J; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Kittel C; Toneatto D; Dull PM; Pollard AJ
    Pediatr Infect Dis J; 2013 Oct; 32(10):1116-21. PubMed ID: 23958808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.
    McQuaid F; Snape MD; John TM; Kelly S; Robinson H; Houlden J; Voysey M; Toneatto D; Kitte C; Dull PM; Pollard AJ
    Pediatr Infect Dis J; 2014 Jul; 33(7):760-6. PubMed ID: 24722351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
    Flacco ME; Manzoli L; Rosso A; Marzuillo C; Bergamini M; Stefanati A; Cultrera R; Villari P; Ricciardi W; Ioannidis JPA; Contopoulos-Ioannidis DG
    Lancet Infect Dis; 2018 Apr; 18(4):461-472. PubMed ID: 29371070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age.
    Snape MD; Voysey M; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Kieninger D; Prymula R; Dull PM; Kohl I; Barone M; Wang H; Toneatto D; Pollard AJ;
    Pediatr Infect Dis J; 2016 Apr; 35(4):e113-23. PubMed ID: 26756390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
    Carter NJ
    BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
    Snape MD; Saroey P; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Wang H; Toneatto D; Dull PM; Pollard AJ
    CMAJ; 2013 Oct; 185(15):E715-24. PubMed ID: 24062178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine.
    Nolan T; Santolaya ME; de Looze F; Marshall H; Richmond P; Henein S; Rheault P; Heaton K; Perrett KP; Garfield H; Gupta A; Ferguson M; D'Agostino D; Toneatto D; O'Ryan M
    Vaccine; 2019 Feb; 37(9):1209-1218. PubMed ID: 30691980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
    Gossger N; Snape MD; Yu LM; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Becker B; Kieninger D; Prymula R; Dull P; Ypma E; Toneatto D; Kimura A; Pollard AJ;
    JAMA; 2012 Feb; 307(6):573-82. PubMed ID: 22318278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.
    Sadarangani M; Sell T; Iro MA; Snape MD; Voysey M; Finn A; Heath PT; Bona G; Esposito S; Diez-Domingo J; Prymula R; Odueyungbo A; Toneatto D; Pollard AJ;
    CMAJ; 2017 Oct; 189(41):E1276-E1285. PubMed ID: 29038320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
    Vesikari T; Esposito S; Prymula R; Ypma E; Kohl I; Toneatto D; Dull P; Kimura A;
    Lancet; 2013 Mar; 381(9869):825-35. PubMed ID: 23324563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
    Iro MA; Snape MD; Voysey M; Jawad S; Finn A; Heath PT; Bona G; Esposito S; Diez-Domingo J; Prymula R; Odueyungbo A; Toneatto D; Dull P; Pollard AJ;
    Vaccine; 2017 Jan; 35(2):395-402. PubMed ID: 27914744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
    Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
    Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
    Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial.
    Martinón-Torres F; Carmona Martinez A; Simkó R; Infante Marquez P; Arimany JL; Gimenez-Sanchez F; Couceiro Gianzo JA; Kovács É; Rojo P; Wang H; Bhusal C; Toneatto D
    J Infect; 2018 Mar; 76(3):258-269. PubMed ID: 29253560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II).
    Esposito S; Prymula R; Zuccotti GV; Xie F; Barone M; Dull PM; Toneatto D
    Hum Vaccin Immunother; 2014; 10(7):2005-14. PubMed ID: 25424810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
    Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
    Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
    Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
    Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
    Snape MD; Dawson T; Oster P; Evans A; John TM; Ohene-Kena B; Findlow J; Yu LM; Borrow R; Ypma E; Toneatto D; Pollard AJ
    Pediatr Infect Dis J; 2010 Nov; 29(11):e71-9. PubMed ID: 20844462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.